ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Eagle Capital Growth Fund Inc

Eagle Capital Growth Fund Inc (GRF)

9.9157
0.0656
(0.67%)
Closed 31 January 8:00AM
9.9157
0.00
(0.00%)
After Hours: 8:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
9.9157
Bid
-
Offer
-
Volume
457
9.76 Day's Range 10.01
8.78 52 Week Range 10.99
Market Cap
Previous Close
9.8501
Open
10.01
Last Trade
100
@
9.9157
Last Trade Time
Financial Volume
US$ 4,483
VWAP
9.8086
Average Volume (3m)
6,772
Shares Outstanding
3,967,836
Dividend Yield
6.86%
PE Ratio
8.53
Earnings Per Share (EPS)
1.16
Revenue
736k
Net Profit
4.61M

About Eagle Capital Growth Fund Inc

The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments.

Sector
Unit Inv Tr, Closed-end Mgmt
Industry
Unit Inv Tr, Closed-end Mgmt
Headquarters
Lutherville Timonium, Maryland, USA
Founded
-
Eagle Capital Growth Fund Inc is listed in the Unit Inv Tr, Closed-end Mgmt sector of the American Stock Exchange with ticker GRF. The last closing price for Eagle Capital Growth was US$9.85. Over the last year, Eagle Capital Growth shares have traded in a share price range of US$ 8.78 to US$ 10.99.

Eagle Capital Growth currently has 3,967,836 shares in issue. The market capitalisation of Eagle Capital Growth is US$39.08 million. Eagle Capital Growth has a price to earnings ratio (PE ratio) of 8.53.

GRF Latest News

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and...

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

SAN CARLOS, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and...

Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash

The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.68 per share in cash. The record date for this distribution is November 29, 2024...

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management...

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare...

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen’s...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1402-1.394206386310.055910.06929.667809.75504099CS
40.27572.859958506229.6410.06929.1730949.64271524CS
12-0.2343-2.3083743842410.1510.998.8567729.9441484CS
260.37573.938155136279.5410.998.8550809.84541025CS
520.965710.78994413418.9510.998.7839179.65614093CS
156-0.2043-2.0187747035610.1211.257.845459.13035917CS
2602.065726.31464968157.8511.255.249198.57581488CS

GRF - Frequently Asked Questions (FAQ)

What is the current Eagle Capital Growth share price?
The current share price of Eagle Capital Growth is US$ 9.9157
How many Eagle Capital Growth shares are in issue?
Eagle Capital Growth has 3,967,836 shares in issue
What is the market cap of Eagle Capital Growth?
The market capitalisation of Eagle Capital Growth is USD 39.08M
What is the 1 year trading range for Eagle Capital Growth share price?
Eagle Capital Growth has traded in the range of US$ 8.78 to US$ 10.99 during the past year
What is the PE ratio of Eagle Capital Growth?
The price to earnings ratio of Eagle Capital Growth is 8.53
What is the cash to sales ratio of Eagle Capital Growth?
The cash to sales ratio of Eagle Capital Growth is 53.48
What is the reporting currency for Eagle Capital Growth?
Eagle Capital Growth reports financial results in USD
What is the latest annual turnover for Eagle Capital Growth?
The latest annual turnover of Eagle Capital Growth is USD 736k
What is the latest annual profit for Eagle Capital Growth?
The latest annual profit of Eagle Capital Growth is USD 4.61M
What is the registered address of Eagle Capital Growth?
The registered address for Eagle Capital Growth is 2405 YORK ROAD, SUITE 201, LUTHERVILLE TIMONIUM, MARYLAND, 21093 2264
Which industry sector does Eagle Capital Growth operate in?
Eagle Capital Growth operates in the UNIT INV TR, CLOSED-END MGMT sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FOXOFOXO Technologies Inc
US$ 0.2553
(14.28%)
6.55M
RIOXDefiance Daily Target 2x Long Riot ETF
US$ 23.44
(11.30%)
220.52k
AUSTAustin Gold Corp
US$ 1.31
(11.02%)
416.41k
CHROChannel Therapeutics Corporation
US$ 2.44
(10.91%)
121.02k
ZONECleanCore Solutions Inc
US$ 1.0762
(9.82%)
39.76k
SGNSigning Day Sports Inc
US$ 2.56
(-41.01%)
3.09M
EXODExodus Movement Inc
US$ 58.96
(-33.98%)
204.24k
DXFEason Technology Limited
US$ 16.53
(-28.04%)
216.99k
OSTXOS Therapies Incorporated
US$ 1.95
(-23.53%)
745.08k
PMNTPerfect Moment Ltd
US$ 0.69
(-18.83%)
113.81k
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2.3599
(-6.17%)
119.52M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 27.15
(5.72%)
86.38M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
US$ 3.32
(-1.19%)
80.8M
FXIiShares China Large Cap
US$ 32.59
(2.39%)
66.66M
XLFFinancial Select Sector
US$ 51.77
(0.96%)
63.42M

Discussion

View Full Feed
DewDiligence DewDiligence 4 minutes ago
MAZE IPOs 10.1* shares @$16.00:

https://www.globenewswire.com/news-release/2025/01/31/3018524/0/en/Maze-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to dev
LovePennyStock LovePennyStock 4 minutes ago
Yep, my first selling order is $5, and my target price is above $9. Let it rock and roll. It will be our first big winner in 2025 !!!!!!
QMMM
rocketeer357 rocketeer357 4 minutes ago
Yup. Looks like the Dodgers vs cannon fodder for at least the 2025 season. Much longer if injuries don't hit LA too hard.

Small market teams are going to find it harder and harder to open the wallet for FA signings and contract extensions. With no plausible shot at doing any better th
DewDiligence DewDiligence 8 minutes ago
Metsera—(MTSR)—IPOs 17.6M* shares @$18.00—raising ~$300M* in_net proceeds:

https://www.globenewswire.com/news-release/2025/01/30/3018515/0/en/Metsera-Announces-Pricing-of-Initial-Public-Offering.html

*Assuming exercise of underwriter’s option.
Risk vs Reward Risk vs Reward 11 minutes ago
True maybe Mo stopped selling for a few hours lol 
KULR
manibiotech manibiotech 11 minutes ago
Hey Ds
You never answered the question in the past as well.
So what is Baker Bros holding of NWBO stock ?
Would ZERO be the right answer ?
NWBO
weedtrader420 weedtrader420 12 minutes ago
☝️🤑☝️
BTCUSD
JusDePomme JusDePomme 18 minutes ago
#1 on breakout board today!!! Wow tomorrow gonna be fun day
AFFU
vinmantoo vinmantoo 21 minutes ago
dewphile, granted we can't really compare the L protein inhibitor from Shionogi and ENTA giving the paucity of data in the Shionogi press release. Just for an exercise let's assume they are measuring the same thing, active virus in a cell culture assay. The difference between viral reduction of 88%
ENTA
littlejohn littlejohn 22 minutes ago
Deepseek had slave labor cost or zero in

the development numbers put out

by many media sites...

Budget breakdown for Development,,,

zero labor cost for years...

zero cost for buildings and equipment...

zero cos
Top Penny Top Penny 22 minutes ago
My song to all the $$$$$$PSRU$$$$ HATERS!!!!

https://www.youtube.com/watch?v=SdJAhvTSsI4
PSRU
Huggy Bear Huggy Bear 22 minutes ago
The HMBL SCAM stock no longer has any IP.

Foote - Lucy.

IP assets - the football.

Shareholders - Charlie Brown.
HMBL
dalesio_98 dalesio_98 24 minutes ago
Lets see what I hear back:

Jan. 30, 2025 6:42 PM ET

Hello,
Please indicate if you are the Transfer Agent for BioAmber Inc (formerly BIOA, BIOAQ) CUSIP number 09072Q106 which filed for Chpt 15 and CCAA in Canada and was liquidated? Shareholders indicate Continen
GVInvestments GVInvestments 26 minutes ago
This guy does great videos on the Elon Musk Tesla scam. https://www.youtube.com/watch?v=X64CMd8ZqCo
TSLA
Top Penny Top Penny 27 minutes ago
Climbing the breakout boards, join me for a drink and a $PSRU conversation!!! Holding Tons!!!

https://www.youtube.com/watch?v=HSFsULRYxCE
PSRU
Top Penny Top Penny 37 minutes ago
Here is to .04+ friend, pour a drink!

https://www.youtube.com/watch?v=oiY_iKSpWLM
PSRU
TightCoil TightCoil 38 minutes ago
I went to bed, but had to get up and try to find out, like i heard on this board,
(a board which, by the way, everyone's idol here, Neo Se Tung, has called a "mental institution), if Queen Sandra Thompson is an assistant to Pulte, the new FHFA Director? Or otherwise, still works at the FHFA
FNMA
skitahoe skitahoe 45 minutes ago
Thanks for the reminder DJ, it pretty much lays out a lot of what we'll see in the future.

One question that really I feel uncertain about is the ability to make the improvements in DCVax-L and put it immediately into a Phase 3 trial.

In other companies when changes wer
NWBO
facts_matter14 facts_matter14 48 minutes ago
4-2-21. Can it be possible to be more wrong?????





https://investorshub.advfn.com/uimage/uploads/2025/1/31/qutyxIMG_6318.jpeg







.
SRMX
USVIHI22 USVIHI22 49 minutes ago
Im in this at .0001. Double or nothing.
GRLF

Your Recent History

Delayed Upgrade Clock